Skip to main content

Advertisement

SpringerLink
Log in

Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5

  • Nephrology – Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background/aims

Anemia is common in patients with chronic kidney disease (CKD). Recently, the erythropoiesis-stimulating agent/hemoglobin level (ESA/Hb) index emerged as a new factor associated with increased morbidity and mortality in this population. In this study, we evaluated the factors that influence the ESA/Hb index in a pre-dialysis CKD population.

Methods

Ninety-five patients were evaluated for clinical and laboratory parameters, nutritional status and ESA/Hb index. For comparison, we divided our population into 3 groups: G I—no ESA treatment, G II—patients with ESA/index below 50th percentile and G III—patients with ESA/Hb index above 50th percentile. We performed single and multiple regression models and logistic regression analysis.

Results

In a multiple regression model, age (t = −3.456, P = 0.001), SGA (t = 2.059, P = 0.047), ferritin (t = 2.386, P = 0.027), Ca × P (t = 2.066, P = 0.043), TNF-α (t = 2.673, P = 0.009) and IL-6 (t = 2.939, P = 0.004) independently influenced the ESA/Hb index. At logistic regression analysis, gender, cardiovascular disease and TNF-α were independently associated with ESA/Hb higher than 50th percentile compared to the other patients (R 2 = 0.457).

Conclusion

In a pre-dialysis population, female gender, cardiovascular disease, malnutrition and inflammation are associated with a higher ESA/Hb index.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Eschbach JW, Adamson JW (1985) Anemia of end-stage renal disease. Kidney Int 28:1–5

    Article  PubMed  CAS  Google Scholar 

  2. Winearls CG, Oliver DO, Pippard MJ et al (1986) Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 2:1175–1177

    Article  PubMed  CAS  Google Scholar 

  3. Eschbach JW, Egrie JC, Downing MR et al (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of phase I and II clinical trial. N Engl J Med 316:73–78

    Article  PubMed  CAS  Google Scholar 

  4. Wingard RL, Parker RA, Ismail L et al (1995) Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25:433–439

    Article  PubMed  CAS  Google Scholar 

  5. Silverberg DS, Wexler D, Blum M et al (2003) The cardio-renal anaemia syndrome: does it exist? Nephrol Dial Transplant 18(Suppl 8):viii7–viii12

    PubMed  Google Scholar 

  6. Collins AJ, Li S, Peter W et al (2001) Death, hospitalization and economic associations among incident haemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12:2465–2473

    PubMed  CAS  Google Scholar 

  7. Foley RN (2002) Anaemia: cardiovascular adaptations and maladaptative responses in chronic kidney disease. Nephrol Dial Transplant 17(Suppl 11):32–34

    PubMed  CAS  Google Scholar 

  8. Astor BC, Coresh J, Heiss G et al (2006) Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 151:492–500

    Article  PubMed  Google Scholar 

  9. Leeder SR, Mitchell P, Liew G et al (2006) Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: the Blue Mountains Eye study. J Am Soc Nephrol 17:279–288

    Article  PubMed  Google Scholar 

  10. Tong EM, Nisseson AR (2001) Erythropoietin and anemia. Semin Nephrol 21:190–203

    Article  PubMed  CAS  Google Scholar 

  11. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Section IV (2004) Failure to respond to treatment. Nephrol Dial Transplant 19(suppl 2):ii32–ii36

    Google Scholar 

  12. Macdougall IC, Cooper AC (2002) Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17(Suppl 11):39–43

    PubMed  CAS  Google Scholar 

  13. Stenvinkel P (2003) Anaemia and inflammation: what are the implications for the nephrologists? Nephrol Dial Transplant 18(Suppl 8):viii17–viii22

    PubMed  Google Scholar 

  14. Kalantar-Zadeh K, Ikizler TA, Block G et al (2003) Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 42:864–881

    Article  PubMed  Google Scholar 

  15. Neves PL, Morgado E, Faísca M et al (2006) Nutritional and inflammatory status influence darbepoietin dose in pre-dialysis elderly patients. Int Urol Nephrol 38:811–813

    Article  PubMed  CAS  Google Scholar 

  16. Kanbay M, Perazella MA, Kasapoglu B et al (2010) Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 29(1):1–12

    Article  PubMed  Google Scholar 

  17. Cotter DJ, Stefanik K, Zhang Y et al (2004) Hematocrit was not validated as a surrogate end point for survival among epoietin-treated hemodialysis patients. J Clin Epidemiol 57:1086–1095

    Article  PubMed  Google Scholar 

  18. Zhang Y, Thamer M, Stefanik K et al (2004) Epoietin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44:866–876

    PubMed  CAS  Google Scholar 

  19. Regidor DL, Kopple JD, Kovesdy CP et al (2006) Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17:1181–1191

    Article  PubMed  CAS  Google Scholar 

  20. Lopez-Gomez JM, Porto J, Aljama P (2008) Factors that condition the response to erythropoeitin in patients on hemodialysis and their relation to mortality. Kidney Int 74:S75–S81

    Article  Google Scholar 

  21. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum craetinine: a new prediction equation. Ann Intern Med 130:461–470

    PubMed  CAS  Google Scholar 

  22. Hsu C, McCulloch CE, Curhan GC (2002) Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13:504–510

    Article  PubMed  Google Scholar 

  23. Sarnak MJ, Tighiouart H, Guruprasad M et al (2002) Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 40:27–33

    Article  PubMed  Google Scholar 

  24. Kuriyama S, Tomonari H, Yoshida H et al (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non diabetic patients. Nephron 77:176–185

    Article  PubMed  CAS  Google Scholar 

  25. Neves PL, Morgado E, Baptista A et al (2007) Anaemia and interleukin-6 are associated with a faster progression to end-stage renal disease. Dial Transplant 36:445–456

    Article  Google Scholar 

  26. Jungers P, Choukroun G, Oualin Z et al (2001) Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16:307–312

    Article  PubMed  CAS  Google Scholar 

  27. Lim VS, DeGowin RL, Zavala D et al (1989) Recombinant human erythropoietin treatment in predialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110:108–114

    PubMed  CAS  Google Scholar 

  28. Revicki DA, Brown RE, Feeny DH et al (1995) Health-related quality of life associated with recombinant human erythropoietin therapy in predialysis chronic renal disease patients. Am J Kidney Dis 25:548–554

    Article  PubMed  CAS  Google Scholar 

  29. Fink J, Blahut S, Reddy M et al (2001) Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37:348–355

    Article  PubMed  CAS  Google Scholar 

  30. Maddux FW (2007) Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Ann Pharmacother 41:1761–1769

    Article  PubMed  Google Scholar 

  31. Drueke TB, Locatelli F, Clyne N et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355(20):2071–2084

    Article  PubMed  CAS  Google Scholar 

  32. Singh AK, Szczech L, Tang KL et al (2006) Correction of anemia with epoietin alfa in chronic kidney disease. N Engl J Med 355:2085–2098

    Article  PubMed  CAS  Google Scholar 

  33. Pfeffer MA, Burdmann EA, Chen CY et al (2009) A trial of darbepoietin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032

    Article  PubMed  Google Scholar 

  34. Locatelli F, Andrulli S, Memoli B et al (2006) Nutritional-inflammation status and resistance to erythropoietin therapy in hemodialysis patients. Nephrol Dial Transplant 21:991–998

    Article  PubMed  CAS  Google Scholar 

  35. Barany P, Divino Filho JC, Bergstrom J (1997) High C-reactive protein is a strong predictor of resistance to erythropoeitin in hemodialysis patients. Am J Kidney Dis 29:565–568

    Article  PubMed  CAS  Google Scholar 

  36. Wei M, Bargman JM, Oreopoulus DG (2007) Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol 39(3):935–940

    Article  PubMed  CAS  Google Scholar 

  37. Stenvinkel P, Barany P (2002) Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. Nephrol Dial Transplant 17(suppl 5):32–37

    Article  PubMed  CAS  Google Scholar 

  38. Stenvinkel P, Heimbürger O, Lindholm B et al (2000) Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 15:953–960

    Article  PubMed  CAS  Google Scholar 

  39. Kalantar-Zadeh K, Block G, McAllister CJ et al (2004) Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 80:297–307

    Google Scholar 

  40. McKevitt PM, Jones JF, Lane DA et al (1990) The elderly on dialysis. Some considerations in compliance. Am J Kidney Dis 16:346–350

    PubMed  CAS  Google Scholar 

  41. Bonanno G, Urso S, Lo Faro F et al (1996) Parathyroid hormone in a population of elderly patients on hemodialysis (preliminary data). Arch Gerontol Geriatr 22:441–445

    Article  PubMed  Google Scholar 

  42. Di lorio B, Stellato D, De Santo N et al (2004) Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status. Blood Purif 22:423–427

    Article  Google Scholar 

  43. Ifudu O, Uribarri J, Rajwani I et al (2001) Gender modulates responsiveness to recombinant erythropoietin. Am J Kidney Dis 38:518–522

    Article  PubMed  CAS  Google Scholar 

  44. Bamgbola OF, Kaskel FJ, Coco M (2009) Analyses of age, gender and other risk factors of EPO resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol 24:571–579

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Serviço de Nefrologia, Hospital de Faro, Rua Leão Penedo, 8000-342, Faro, Algarve, Portugal

    Ana de Lurdes Agostinho Cabrita, Ana Pinho, Anabela Malho, Elsa Morgado, Marília Faísca, Hermínio Carrasqueira, Ana Paula Silva & Pedro Leão Neves

Authors
  1. Ana de Lurdes Agostinho Cabrita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Pinho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anabela Malho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elsa Morgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marília Faísca
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hermínio Carrasqueira
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ana Paula Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pedro Leão Neves
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana de Lurdes Agostinho Cabrita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Lurdes Agostinho Cabrita, A., Pinho, A., Malho, A. et al. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Int Urol Nephrol 43, 835–840 (2011). https://doi.org/10.1007/s11255-010-9805-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-010-9805-9

Keywords

Search

Navigation